ReviewRespirology (Carlton, Vic.)2021
Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand.
Review in Respirology (Carlton, Vic.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05870215 (Phenotyping Responses to Systemic Corticosteroids in the Management of Asthma Attacks), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phenotyping Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA): Clinical and Translational Correlation to Point-Of-Care Biomarkers
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Radiofrequency ablation of inferior turbinates for rhinitis medicamentosa: a systematic review and case series.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Pooled it
- Trial
- Treatable Trait Guided Asthma Management: A Feasibility Study.Respirology (Carlton, Vic.) · 2025Trial
- A new era beckons in asthma: enhanced models of care, disease remission, artificial intelligence and consumer participation.Internal medicine journal · 2026Review
- Article
- Diagnostic Overshadowing in Chronic Obstructive Pulmonary Disease: A Case of Recurrent Syncope.Cureus · 2026Article
- A computational phenotype for difficult-to-treat asthma with corticosteroid overuse using electronic health care records.The journal of allergy and clinical immunology. Global · 2026Article
- Campesterol attenuates airway inflammation in allergic asthma: insights from a murine model and molecular docking analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Real-World Effectiveness Following Benralizumab Use in Patients with Severe Eosinophilic Asthma in Romania: A Retrospective Cohort Study (BREEZE).Journal of clinical medicine · 2026Article
- Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission.The Korean journal of internal medicine · 2026Observational
- Key priorities to prevent avoidable asthma hospitalisations: insights from end-users.ERJ open research · 2026Article
- Corticosteroid-induced Cushingoid Appearance in Myasthenia Gravis.Internal medicine (Tokyo, Japan) · 2025Article
- Clinical Remission in Severe Asthma: A Comparative Analysis of Patients with and Without Biologics from the Swiss Severe Asthma Registry.Biomedicines · 2025Article
- Review
- Increased eosinophils after oral corticosteroid treatment for asthma exacerbation correlated with longer ER stays and persisting thymic stromal lymphopoietin and increased Park2.Scientific reports · 2025Article
- A case scenario study on adherence to GINA recommendations by primary care physicians in an area of Southern Italy: the "Progetto Padre 2.0".BMC primary care · 2025Observational
- Biologic Therapies for Severe Asthma: Current Insights and Future Directions.Journal of clinical medicine · 2025Review
- Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA).The European respiratory journal · 2025Observational
- Treatment of lung diseasesMaterials today. Bio · 2025Review
- International Severe Asthma Registry (ISAR): 2017-2024 Status and Progress Update.Tuberculosis and respiratory diseases · 2025Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral corticosteroids (OCS) are frequently used for asthma treatment. This medication is highly effective for both acute and chronic diseases, but evidence indicates that indiscriminate OCS use is common, posing a risk of serious side effects and irreversible harm. There is now an urgent need to introduce OCS stewardship approaches, akin to successful initiatives that optimized appropriate antibiotic usage. The aim of this TSANZ (Thoracic Society of Australia and New Zealand) position paper is to review current knowledge pertaining to OCS use in asthma and then delineate principles of OCS stewardship. Recent evidence indicates overuse and over-reliance on OCS for asthma and that doses >1000 mg prednisolone-equivalent cumulatively are likely to have serious side effects and adverse outcomes. Patient perspectives emphasize the detrimental impacts of OCS-related side effects such as weight gain, insomnia, mood disturbances and skin changes. Improvements in asthma control and prevention of exacerbations can be achieved by improved inhaler technique, adherence to therapy, asthma education, smoking cessation, multidisciplinary review, optimized medications and other strategies. Recently, add-on therapies including novel biological agents and macrolide antibiotics have demonstrated reductions in OCS requirements. Harm reduction may also be achieved through identification and mitigation of predictable adverse effects. OCS stewardship should entail greater awareness of appropriate indications for OCS prescription, risk-benefits of OCS medications, side effects, effective add-on therapies and multidisciplinary review. If implemented, OCS stewardship can ensure that clinicians and patients with asthma are aware that OCS should not be used lightly, while providing reassurance that asthma can be controlled in most people without frequent use of OCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.